Bagi R.P. Jana, MD, MBA, MHA, FACP
Department of General Oncology, Division of Cancer Medicine
About Bagi R.P. Jana
Dr. Bagi Jana joined the faculty of UTMB division of Medical Oncology and Hematology in 2011. He earned his medical degree at the Madras Medical College in Chennai, India in 1990. He completed his Internal Medicine Residency at the University of Illinois College of Medicine and went on to complete his fellowship in Medical Oncology and Hematology at the Mount Sinai Medical Center, New York University, New York.
Certified by the American Board of Internal Medicine (1997), Medical Oncology (2000 & recertified 2010) and Hematology (2003), Dr. Jana brings more than a decade of experience in providing high quality and compassionate cancer care. His research interests focus on improving the outcome of Genito urinary malignancies namely Prostate, Urinary bladder and Kidney cancers. Dr. Jana is actively engaged in clinic research and strives to provide the best modern cutting edge multi disciplinary care at UTMB.
Dr. Jana is a member of American Society of Clinical Oncology, American Medical Association, American Association of Cancer Research, American Society of Hematology, RTOG and SWOG. He has authored or co-authored several peer reviewed journal publications involving original research, abstracts and book chapters.
Read More
Present Title & Affiliation
Primary Appointment
Medical Oncology Section Chief-MDACC/UTMB Health Galveston Medical Oncology & Hematology Program, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Galveston, TX
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Department of General Oncology, Division of Cancer Medicine, The University of Texas Medical Branch, Galveston, TX
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas Medical Branch, Galveston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Houston, Clear Lake, Clear Lake, Texas, US, Business, MHA |
| 2016 | University of Houston, Clear Lake, Clear Lake, Texas, US, Business, MBA |
| 1990 | Madras Medical College and General Hospital, Tamil Nadu, IN, MD |
Postgraduate Training
| 1997-2000 | Clinical Fellowship, Medical Oncology and Hematology, Mount Sinai Medical Center, New York, New York |
| 1994-1997 | Clinical Residency, Christ Hospital and Medical Center, Chicago, Illinois |
| 1993-1994 | Clinical Internship, Pathology, University of Illinois, Chicago, Illinois |
| 1991-1993 | Senior House Officer, General Hospital, Tamil Nadu |
Board Certifications
| 2013 | Hematology, Diplomate |
| 2012 | Hospice and Palliative Care Medicine, Diplomate |
| 2010 | Medical Oncology, Diplomate |
Experience & Service
Academic Appointments
Associate Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2012 - 2017
Assistant Professor, The University of Texas Medical Branch, Galveston, TX, 2011 - 2012
Assistant Professor, The University of Central Florida College of Medicine, Orlando, FL, 2007 - 2011
Assistant Professor, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 2003 - 2007
Assistant Professor, Cancer Institute of Chennai, Chennai, 2001 - 2003
Instructor, Mount Sinai School of Medicine, New York, NY, 1997 - 2000
Administrative Appointments/Responsibilities
Medical Oncology Section Chief-MDACC/UTMB Health Galveston Medical Oncology & Hematology Program, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Galveston, TX, 2023 - Present
Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2017 - 2018
Medical Director, Department of Hospice, The University of Texas Medical Branch, Texas City, TX, 2012 - 2017
Subspecialty Co-Coordinator, Department of General Oncology, The University of Texas Medical Branch, Orlando, FL, 2009 - 2011
Institutional Committee Activities
Contributor, UTMB Medical Staff and Executive Committee
Chair, UTMB Pharmacy and Therapeutics Subcommittee
Contributor, UTMB Urology Tumor Board
Contributor, MDACC Urology Tumor Board
Contributor, Institutional Review Board at UTMB
Contributor, MDACC ICCI (Value-based Care Committee)
Contributor, UTMB High Value Healthcare Committee
Honors & Awards
| 2015 | Elected as Fellow in American College of Physicians |
| 2015 | TOP DOCTOR: Selected as a TOP DOCTOR by peers (Oncology and Hematology) by Houstonia |
| 1997 | Winner of 1997 ACP Associates Clinical Vignette Competition: One of Seven Associates in United States Invited for Oral Presentation at the American College of Physicians 78th Annual Session in Philadelphia, PA |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Williams, TP, Cox, MW, Jana, BR, Ross, MI, Fisher, SB, Walker, JP, Hume, CB, Mayo, LL, Tyler, DS. Vascular Stenting of a Malignant Arterial Blowout as a Bridge to Effective Systemic and Regional Therapy. J Surg Onc 129(7):1209-1212, 2024. PMID: 38534025.
- Fan, J, Thanedar, S, Ovechko, V, Jana, BR. Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers. Case Reports in Oncology 17(1):517-523, 2024. PMID: 38549625.
- Jun T, Hahn NM, Sonpavde G, Albany C, MacVicar GR, Hauke R, Fleming M, Gourdin T, Jana B, Oh WK, Taik P, Wang H, Varadarajan AR, Uzilov A, Galsky MD. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist 27(6):432-e452, 2022. PMID: 35438782.
- Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Eur Urol Oncol 2(5):497-504, 2019. e-Pub 2018. PMID: 31411998.
- Jana BR, Zhou Y. Novel Molecular Targets for the Therapy of Urothelial Cancer. Anticancer Res 35(None):4557-4567, 2015. PMID: None.
- Al Asad O, Salam A, Mannem S, Ninan M, Markowitz A, Jana B. Alternative Therapy for Epstein Barr virus Related Hemophagocytic Lymphohistiocytosis. Case Rep Oncol Med None(None):None, 2015. PMID: None.
- Jana B, Khanfar A, Ninan M. Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide. Case Reports in Oncological Medicine None(None):None, 2014. PMID: None.
- Koshy J, Alperin J, Jana B, Markowitz A, Qian YW. A Case of Philadelphia Chromosome Positive Myeloproliferative Neoplasm in a Pregnant Woman with Unusual Primary Myelofibrosis Features. Case Rep Hematol None(None):None, 2013. PMID: None.
- Khanfar A, Trikha A, Bonds R, Jana B. Angioedema with Normal C1q and C1 Inhibitor: An atypical presentation of Waldenström macroglobulinemia. Int J Hem 97(None):654-6, 2013. PMID: None.
- Ghadimi-Mahani M, McDonnold Mollie A, Jana B, Markowitz A, Willis M, Harirah H. Sarcomatoid Carcinoma of the Oral Cavity during Pregnancy. Case Reports in Perinatal Medicine 25(None):None, 2013. PMID: None.
- Jana BR, Galsky MD, Hahn NM, Milowsky MI, Sonpavde G. Novel Molecular Targets for the Therapy of Urothelial Carcinoma. None 16(None):499-513, 2012. PMID: None.
- Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Bagirathan J, Cheney RT. ERBB2 Juxtamembrane Domain (trastuzumab binding site) Gene Mutation is a Rare Event in Invasive Breast Cancers Overexpressing the ERBB2 Gene. Mod Pathol 24(None):1055-9, 2011. PMID: None.
- Hicks DG, Janarthanan BR, Vardarajan R. The Expression of TRMT2A, a Novel Cell Cycle Regulated Protein, identifies a Subset of Breast Cancer Patients with HER2 Over-expression that are at an Increased Risk of Recurrence. BMC Cancer None(None):None, 2010. PMID: None.
- Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Geradts J. Sam-pointed Domain Containing Ets Transcription Factor in Luminal Breast Cancer Pathogenesis. Cancer Epidemiol Biomarkers Prev None(None):None, 2009. PMID: None.
- Seitz R, Ross D, Ring B. Validation of an Immunohistochemical Biomarker for Identifying Her2+ Patients at High Risk of Recurrence. Breast Cancer Research and Treatment None(None):S248, 2007. PMID: None.
- Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR. Prognosis of Occult Breast Carcinoma Presenting as Isolated Axillary Nodal Metastasis. Oncology None(None):456-9, 2006. PMID: None.
- Tan D, Wu X, Hou M, Lee S, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump D, Gao A. Interleukin-6 Polymorphism is Associated with More Aggressive Prostate Cancer. J Urol 174(None):753-6, 2005. PMID: None.
- Berkelhammer C, Janarthan B, Bhagavan M, Schreiber S. Hepatocolic Fistula and Lower GI Bleeding in Hepatoma. Am J Gastroenterol None(None):26254-6, 1996. PMID: None.
Other Articles
- Nelson BE, Hong A, Jana B Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. Front Oncol 11:705294, 2021. PMID: 34422659.
- Nelson BE, Hong A, Dekmezian M, Jana B Standard-Dose Rituximab as Effective Therapy for Treating Malignancy-Related Hemophagocytic Lymphohistiocytosis in the Eldery: A Case Report. Case Rep Oncol 14(2):1066-1070, 2021. PMID: 34326743.
- Nelson BE, Hong A, Iqbal F, Jana B A Unique Case of Hemolytic-uremic Syndrome Secondary to Enteropathogenic E Coli. Clin Case Rep 8(12):2625-2628, 2020. PMID: 33363792.
- Kesireddy M, Mendiola VL, Jana B, Patel S Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved. Cureus 11(8):e5383, 2019. PMID: 31616614.
- Turbiville D, Du X, Yo J, Jana BR, Dong J Iron Overload in an HFE Heterozygous Carrier: A Case Report and Literature Review. Lab Med 50(2):212-217, 2019. PMID: 30339210.
- Mendiola VL, Kesireddy M, Jana B Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report. Case Rep Oncol Med 2019(None):6759472, 2019. PMID: 31949965.
- Venkatesan R, Hirani N, Willis M, Jana B, Cheema Z Impending Carotid Blowout from a Large Neck Mass Treated Sequentially with Endovascular Coil Embolization Followed by Induction Chemotherapy. J Oncol Pract 14(2):136-138, 2018. PMID: 29016223.
- Mendiola VL, Qian YW, Jana B Septic Shock Predisposed by an Underlying Chronic Neutrophilic Leukemia with an Atypical Presentation; A Case Report. Case Rep Oncol 11(3):871-879, 2018. PMID: 30687064.
Abstracts
- Ngishu R, Aterno M, Jana B. A Case of Refractory Hemophagocytic Lymphohistiocytosis in a Young Woman with Systemic Lupus Erythematosus. None None(None):None, 2016. PMID: None.
- Steinberg GD, Curti B, Sachdeva K, Katz MH, Jana B. Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Medscape None(None):None, 2016. PMID: None.
Book Chapters
- Steinberg GD, Curti B, Sachdeva K, Katz MH, Jana B. Transurethral Resection of Bladder Tumors Overview of TURBT. In: Medscape. None. None, None, 2016.
- Sachdeva K, Curti B, Makhoul I, Jana B. Testicular Cancer. In: Medscape. None. None, 2016.
- Steinberg GD, Brosman SA, Curti B, Jana B, Jiang Z, Stephen J, Jones, Katz MH, Levy DA, Lu D, Sachdeva K. Bladder Cancer. In: Medscape. None. None, None, 2016.
- Jana BR, Kush S. Adrenal Carcinoma Clinical Presentation. In: Medscape. None. None, None, 2016.
- Steinberg GD, Curti B, Jana B, Katz MH, Sachdeva K. None. In: Urine Tumor Markers in Bladder Cancer Diagnosis. None. None, None, 2016.
- Kush S, Bagi J. Nonseminoma Testicular Cancer Treatment Protocols. In: Medscape. None. None, None, 2016.
- Kush S, Jana Bagi RP. Nonseminoma Testicular Cancer Staging. In: Medscape. None. None, None, 2016.
- Steinberg GD, Curti B, Jana B, Jones JS, Katz MH, Levy DA, Sachdeva K. Cystoscopy Overview of Cystoscopy. In: Medscape. None. None, None, 2016.
- Curti B, Jana BR, Mansoor J, Makhoul I, Sachdeva K. Renal Cell Carcinoma. In: Medscape. None. None, None, 2016.
- Jana B. Prostate Cancer Guidelines. In: Medscape. None. None, None, 2016.
- Kush S, Makhoul I, Curti B, Jana B. None. In: Extragonadal Germ Cell Tumors. None. None, None, 2016.
- Jana BR, Kush S. Renal Transitional Cell Carcinoma. In: Medscape. None. None, None, 2016.
- Kush S, Jana Bagi RP. Seminoma Testicular Cancer Staging. In: Medscape. None. None, None, 2016.
- Nallapareddy S, Janarthanan B, Kamasani S. Esophageal Cancer in a Post-Liver Transplant Patient. In: Internet Journal of Gastroenterology. 1. None, None, 2005.
- Jana B. Cabazitaxel improves survival in castration resistant prostate cancer patients with progression on docetaxel. In: Community Oncology. None. Community Oncology, 542-3, 2000.
Grant & Contract Support
| Title: | A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy PROSPER RCC |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | An Open-Label, Phase 1b Study of ACP-196 in Subjects with Multiple Myeloma Pharmaceutical Industry Study |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Phase III Trial of Enzalutamide (Nsc 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices |
| Funding Source: | Incyte Corporation |
| Role: | PI |
| Title: | Everest: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Androgen Deprivation Therapy with or without Radium-223 Dichloride In Patients with Newly Diagnosed Metastatic Prostate Cancer with Bone Metastases |
| Funding Source: | HOG Consortium Study |
| Role: | Co-I |
| Title: | Study of Expression Patterns of Fortilin in Prostate and Breast Cancers and its Association with Clinical Features, Prognosis and Treatment Outcome Pilot Translational Research Project (pi initiated no funds) |
| Funding Source: | Unknown |
| Role: | Co-I |
| Title: | Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Diease Registry |
| Funding Source: | Celgene |
| Role: | PI |
| Title: | Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-Line Therapy In Cisplatin-Ineligible Participants with Advanced Urothelial Carcinoma |
| Funding Source: | Hoosier Oncology Group HOG Consortium Study |
| Role: | PI |
| Title: | An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) Pharmaceutical Study Retrospective Data Analysis Research |
| Funding Source: | Unknown |
| Role: | Co-I |
| Title: | A Randomized Phase II Study of Androgen Deprivation Combined with Imc-A12 versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A Randomized Phase II Study of Androgen Deprivation Combined with Imc-A12 versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Effect of Cross Talk between Estrogen Receptor, HER-2/neu, and Tumor Suppressor p53 Signaling Pathways on Tamoxifen Resistance in Breast Cancer |
| Funding Source: | DOD-CONCEPT |
| Role: | Co-I |
| Title: | A Randomized, Phase II Efficacy Assessment of Multiple Met-Kinase Inhibitors (Cabozantinib [Nsc #761968], Crizotinib [Nsc #749005], Savolitinib [Nsc #785348], And Sunitinib [Nsc #736511]) in Metastatic Papillary Renal Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
Patient Reviews
CV information above last modified September 24, 2024